Command Palette

Search for a command to run...

Clinical Trials · NCT01387347

Safety and Efficacy of Thymosin Beta 4 Ophthalmic Solution in Patients With Dry Eye

CompletedPhase 2TB-500 (Approved)
Phase
Phase 2
Recruitment status
Completed
Sponsor
ReGenTree, LLC
Enrollment
72
Start date
Aug 2011
Locations
See registry
Primary endpoint
Corneal Staining (Inferior Region) in the Worst Eye in the Controlled Adverse Environment (CAE) Model, Which is a Regulated Environmental Setting Aimed at Exacerbating the Signs and Symptoms of Dry Eye
View TB-500 compound reference